Your Yourlocation: Home > Pharmacokinetics of tiotropium bromide(136310-93-5) in elderly patients and hepatic insufficiency

Patient-specific Elderly Patients: As with all major renal excretion, tiotropium bromide(136310-93-5) has decreased renal clearance in elderly patients (younger than 58 years of age with a COPD of 326 ml /min; COPD older than 70 years Patients, the clearance rate of 163ml /min). This may be related to decreased renal function. The urinary excretion of tiotropium after inhalation decreased from 14% (young healthy volunteers) to about 7% (COPD patients); however, the variability between individual and individual patients (dry powder inhaled AUC0-4 Increased by 43%) compared with the plasma concentration of COPD patients did not increase with age and significant changes. 

Patients with renal insufficiency: As with all other major renal excretion drugs, intravenous or dry powder inhalation increases renal function and the renal clearance of the drug decreases. In the elderly, the more common mild renal dysfunction (CLCR50-80ml /min), tiotropium bromide(136310-93-5) plasma concentration can be mildly increased (intravenous injection of AUC0-4 increased 39%). In patients with moderate to severe renal insufficiency (CLCR <50 ml /min), the plasma concentration doubled after intravenous administration of tiotropium bromide (AUC0-4 increased by 82%) and plasma concentrations after dry powder inhalation were also increased. In this case, Patients with hepatic insufficiency: Liver dysfunction has no effect on the pharmacokinetics of tiotropium bromide(136310-93-5). Tiotropium was mainly excreted by renal excretion (74% in young healthy volunteers), with a small amount of non-enzymatic ester decomposition into non-pharmacological activity of the product.

Address: TEL:0531-82375879 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved